- Home
- YGMZ vs VINC Comparison
YGMZ vs VINC Comparison
Compare YGMZ & VINC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YGMZ
- VINC
- Stock Information
- Founded
- YGMZ 2002
- VINC 2019
- Country
- YGMZ China
- VINC United States
- Employees
- YGMZ N/A
- VINC N/A
- Industry
- YGMZ Transportation Services
- VINC Biotechnology: Pharmaceutical Preparations
- Sector
- YGMZ Consumer Discretionary
- VINC Health Care
- Exchange
- YGMZ Nasdaq
- VINC Nasdaq
- Market Cap
- YGMZ 7.5M
- VINC 6.2M
- IPO Year
- YGMZ 2020
- VINC N/A
- Fundamental
- Price
- YGMZ $1.03
- VINC $0.22
- Analyst Decision
- YGMZ
- VINC Buy
- Analyst Count
- YGMZ 0
- VINC 2
- Target Price
- YGMZ N/A
- VINC $2.00
- AVG Volume (30 Days)
- YGMZ 19.5K
- VINC 557.0K
- Earning Date
- YGMZ 01-01-0001
- VINC 11-12-2024
- Dividend Yield
- YGMZ N/A
- VINC N/A
- EPS Growth
- YGMZ N/A
- VINC N/A
- EPS
- YGMZ N/A
- VINC N/A
- Revenue
- YGMZ $89,002,243.00
- VINC N/A
- Revenue This Year
- YGMZ N/A
- VINC N/A
- Revenue Next Year
- YGMZ N/A
- VINC N/A
- P/E Ratio
- YGMZ $14.50
- VINC N/A
- Revenue Growth
- YGMZ N/A
- VINC N/A
- 52 Week Low
- YGMZ $0.91
- VINC $0.18
- 52 Week High
- YGMZ $6.24
- VINC $9.37
- Technical
- Relative Strength Index (RSI)
- YGMZ 35.59
- VINC 38.03
- Support Level
- YGMZ $1.04
- VINC $0.19
- Resistance Level
- YGMZ $1.25
- VINC $0.23
- Average True Range (ATR)
- YGMZ 0.09
- VINC 0.03
- MACD
- YGMZ 0.00
- VINC 0.00
- Stochastic Oscillator
- YGMZ 8.33
- VINC 29.74
About YGMZ MingZhu Logistics Holdings Limited
MingZhu Logistics Holdings Ltd is a Holding company. Its business activities include trucking services and car owner services. Its segments are the trucking business, car owner services business, and liquor distribution business. It generates the majority of its revenue from the trucking segment.
About VINC Vincerx Pharma Inc.
Vincerx Pharma Inc is a clinical-stage biopharmaceutical company focused on development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The company's activities are conducted in the United States. It focuses on developing, using, manufacturing, commercializing, sublicensing, and distributing a clinical-stage and follow-on small molecule drug program and a preclinical-stage bioconjugation/next-generation ADC platform.